Select Page

Anti-Human IL 12/23 (Briakinumab) – HRP – 100 µg

ST0034-2
NA

$303.45

DATA SHEET

ImmunogenThis antibody was produced by phage display technology.
FormulationThis HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)
Description/BackgroundBriakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
Storage TemperatureThis horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.
Protocols
Clone NumberABT-874
Concentration0.5 mg/ml
Regulatory StatementFor Research Use Only. Not for use in diagnostic procedures.
ST0034-2
NA

$303.45

SIGN UP